Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 86 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle of Test Product Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis

NCT06742957
View directory record Official record
Conditions
Plaque Type Psorisis
Interventions
Tapinarof Cream 1%, VTAMA®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
26
States / cities
Scottsdale, Arizona • Bryant, Arkansas • Dublin, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

NCT03650361
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.3%, Differin 0.3% Topical Gel, Adapalene Gel 0.3% Vehicle Placebo
Drug
Lead sponsor
Aleor Dermaceuticals Limited
Industry
Eligibility
12 Years to 40 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Sherman Oaks, California • Brandon, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis

NCT02616601
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Generic Fluorouracil Cream, Carac® (Fluorouracil) Cream, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Study of 0417 Ointment in the Treatment of Atopic Dermatitis

NCT01139450
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0417, Vehicle of 0417 test product, Tacrolimus Ointment 0.03%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.

NCT06673654
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib Topical Cream 1.5%, OPZELURA (Ruxolitinib) Cream, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years and older
Enrollment
476 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04134273
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CLPG Topical Gel 1%, Clindamycin, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

NCT03393494
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

NCT07215767
View directory record Official record
Conditions
Dentin Hypersensitivity
Interventions
Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice, Vehicle Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
12 Years to 65 Years
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Melbourne, Florida • Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle

NCT02578771
View directory record Official record
Conditions
Surgical Site Infection
Interventions
ZuraPrep with 70% IPA, ZuraPrep without 70% IPA, ChloraPrep CHG/IPA Teal Tint, Normal Saline
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04321070
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Clindamycin Phosphate RLD, Placebos
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis

NCT05763082
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
roflumilast cream 0.3%, Zoryve, Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma

NCT02855450
View directory record Official record
Conditions
Glaucoma
Interventions
rhNGF, Vehicle
Drug
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 11, 2026, 12:59 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation

NCT02802436
View directory record Official record
Conditions
Healing of Extraction Socket
Interventions
Extraction with socket graft
Procedure
Lead sponsor
Boston University
Other
Eligibility
20 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis

NCT02654769
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
22
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation

NCT01430312
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre-foam formulation, Vehicle pre-foam formulation, Water, Sodium lauryl sulfate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold

NCT03005067
View directory record Official record
Conditions
Common Cold
Interventions
Carbomer 980 (1146A), Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 11, 2026, 12:59 PM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 11, 2026, 12:59 PM EDT